After a week of being too close to call, Californias Proposition 14 has passed, allowing the state to issue $5.5 billion in bonds for stem cell research.
The measure flew under the radar early in the election season, with almost no opposition and $15 million spent by proponents. But Californians were split on the measure, with just 51% of residents voting yes as of Nov. 12 when the race was called.
Proposition 14 was brought forward by real estate developer Robert Klein, who formerly served as board chairman of the California Institute for Regenerative Medicine (CIRM). The agency was created by another ballot proposition in 2004, and remains one of the only state-funded stem cell research agencies in the United States.
John Matsusaka, a University of Southern California economist with a focus on the ballot process, says this measure put a tough decision on voters.
Theres many useful things you might want to do research on, is this the one you want to put so much money into, he asked. This was an interest group who said they wanted to carve out one thing for themselves which raises some questions.
CIRM was envisioned as a mecca of biological discovery that would make California a leader in curing diseases such as Alzheimers, cancer and diabetes. Proponents say a new injection of state funding will help them continue this important work.
But the agency has faced criticism over the years from those who feel the promised research hasnt materialized, and that conflicts of interest have compromised the institutes integrity.
David Jensen, author of a book about the Institute called Californias Great Stem Cell Experiment, says even with the passage of Proposition 14, doubts about the agencys future remain.
[In 2004], people were led to believe that stem cell therapies and cures were right around the corner. That did not turn out to be the case, he said. It's very important to finance stem cell research. The question is, should the state do that?
Controversial Beginnings
California voters were first asked to weigh in on stem cell funding in 2004. At the time, George W. Bush was in the White House and had banned federally funded embryonic stem cell research.
That meant California scientists investigating HIV/AIDS treatments, Parkinson's cures and more were fighting over a trickling well of funding. So they took to the ballot with Proposition 71, which passed with 59% of the votes. That allowed the state to issue $3 billion in bonds for the creation of the California Institute for Regenerative Medicine.
Because of the timing, it was a shot in the arm to the field, said Zach Hall, who served as the first president of CIRM.
Proposition 14 opponents argue that because former President Barack Obama lifted restrictions on embryonic stem cell research, California scientists can now lean on federal grants and private industry funding to carry their work through.
The NIH could support most of the work that CIRM has funded in the past 10 years, and so the rationale for having a new proposition and increasing the amount of money is unclear, Hall said. You could say just as well why dont we have a state agency to fund CRISPR research?
But supporters argue that federal grants are competitive, and there isnt enough money in the national cache or in private industry to backfill what CIRM provides for researchers across the state.
Robert Klein, former chairman of the Institutes board and leader of the campaign supporting Proposition 14, said that without new bond funding, the Institutes existing research projects would be out of money once they reach the ends of their current grant cycles.
Those trials will not have any funding available to take them forward, he said. And we have a pent-up demand waiting for these new funds from Prop 14 for dozens of new trials for new therapies.
Last summer CIRM told researchers it would stop accepting new grant applications, with the exception of $5 million in emergency funding it set aside for COVID-19 research.
Where Did The First $3 Billion Go?
Supporters of Proposition 14 say the work that CIRM has done over the years has brought California to the forefront in stem cell research, and laid the groundwork for cures to hundreds of diseases.
The agency has distributed hundreds of research grants to public and private universities, medical research institutions and for-profit companies.
Nearly 40%of that money has gone into basic research that helps scientists understand stem cells and how they might be used in medicine, according to a San Francisco Chronicle analysis of CIRM spending. The list of conditions researchers have focused on is long, and includes heart disease, Huntingtons, leukemia, Alzheimers and glioblastoma, to name just a few.
CIRM put 16% of the money into building infrastructure, including about a dozen stem cell research centers, according to the analysis. Another $388 million went toward taking research out of the lab and applying it to humans.
Of the 90 clinical trials the Institute has funded, two drugs have earned FDA approval for fatal forms of blood cancer, according to the campaign supporting the proposition.
The campaign reports CIRM-funded researchers have published 2,900 medical discoveries.
From Sacramento to San Francisco to LA to San Diego, these world eminent scientist leaders in this field came together and said we have to have this funding to go forward, Klein said. We cant attract and hold the best scientists in the world unless we can show them that the therapies they work on are going to actually be able to get to patients.
Supporters also argue that Proposition 71 was an economic boon for the Golden State. A 2019 study from the University of Southern California (commissioned by CIRM) estimates that the Institutes impact on Californias economy is $10.7 billion in gross output, $641.3 million in tax revenue and nearly 56,000 jobs created.
But Matsusaka, a USC economics professor who was not affiliated with that study, says hes doubtful that the $5.5 billion that Proposition 14 will inject into stem cell research will be the job-generator California needs now.
This is money thats channeling into research, into scientists, into highly skilled white collar workers who are very fully employed already, he said. If you were pouring money into restaurant workers or something like that I think there could be a stimulating effect because thats where theres a big pool of people who are unemployed right now. Its hard for me to see how pouring money into this could have a stimulating effect.
And he says pulling money out of other sectors to support this work could do harm to the states economy more broadly.
Conflicts of Interest
At several points during its 16-year history, CIRM has been criticized for conflicts of interest between its board and the researchers it supports.
An analysis from the California Stem Cell Report, which has been tracking the agency since its inception, found that Stanford University, UCLA and UC San Diego are the top recipients of CIRM funding, and they all have representatives on the CIRM board.
Far too many board members represent organizations that receive CIRM funding or benefit from that funding, wrote the National Academy of Medicine in a 2012 study of the agency. These competing personal and professional interests compromise the perceived independence of the ICOC (the CIRM governing board), introduce potential bias into the boards decision making, and threaten to undermine confidence in the board.
In 2014, a former CIRM president left his job and almost immediately took a high-paying position at an agency that receives research funding from the Institute. David Jensen with California Stem Cell Report has tracked several other conflict of interest issues within the organization.
He says Proposition 14 changes some legal definitions and increases the number of people on the board from 29 to 35, but does not do anything to ameliorate those problems.
If youve got the dean of the medical school at UC Davis sitting on that board, voting on programs that might benefit his or her institution, legally or not thats still a conflict of interest, he said.
The agency has historically argued that the relationships between its board members and the scientists it supports are in line with its established conflict of interest policies.
After Proposition 14 was declared successful, the campaign supporting it called the measure one of the most important investments our state can make.
Over the past decade, California has made incredibly thoughtful and impactful investments in developing stem cell therapies and cures for diseases and conditions like diabetes, cancer, blindness, Parkinsons, paralysis and many more, wrote Robert and Danielle Klein, with the Californians for Stem Cell Research, Treatments and Cures campaign, in a statement. Now we know this progress and work to mitigate human suffering, restore health and improve the human condition will continue.
The measure will ultimately result in California taking on $7.8 billion dollars in debt, including interest.
Go here to read the rest:
- Paralysed patient now able to walk as stem cell therapy shows promising results - WION - April 15th, 2024
- Andrew Steele Sees Aging as the Root of Disease - Worth - Worth Magazine - April 15th, 2024
- The astonishing effect of stem cell implants - as groundbreaking treatment 'transforms' life for those with brain damage ... - Daily Mail - April 15th, 2024
- Consumer Alert on Regenerative Medicine Products Including Stem Cells - FDA.gov - April 13th, 2024
- This Startup Wants To Be OpenAI Of Stem Cell Therapy, Targets $250B Market - Forbes - April 13th, 2024
- Brain-cell transplants are the newest experimental epilepsy treatment - MIT Technology Review - April 3rd, 2024
- Global Regenerative Medicine Market to Touch Valuation of USD 472.95 Billion by 2032, at 25.86% CAGR: Astute ... - Yahoo Finance - April 1st, 2024
- Explosive Growth Projected for Stem Cell Market, Expected to Surpass $37 Billion by 2030 As Revealed In New... - WhaTech - April 1st, 2024
- Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma - Targeted Oncology - April 1st, 2024
- New tool provides researchers with improved understanding of stem cell aging in the brain - Medical Xpress - March 30th, 2024
- The ISSCR announces 2024 election results - EurekAlert - March 28th, 2024
- Exosomes and Stem Cells Are the Future of Anti-Aging - NewBeauty Magazine - March 28th, 2024
- Charles River Extends Gene Therapy Alliance with NUS Medicine - Contract Pharma - March 22nd, 2024
- Exciting opportunities in stem cell technology and regenerative biology in Indian healthcare industry - Express Healthcare - March 22nd, 2024
- Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine - Yahoo Finance - March 22nd, 2024
- Opinion: The revolutionary sickle cell therapies - MSN - March 22nd, 2024
- 10 Years of Kansas Regenerative Medicine Center - KSAL - March 22nd, 2024
- BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership - Diagnostic and Interventional Cardiology - March 17th, 2024
- Cynata Therapeutics' breakthrough in regenerative medicine - Finance News Network - March 17th, 2024
- New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia - GlobeNewswire - March 17th, 2024
- Novel 3D stem cell therapy to treat critical limb ischaemia - Drug Target Review - March 15th, 2024
- Breaking Boundaries: Pharmicell's Bold Vision for Healthcare Transformation and Monumental Growth - The Worldfolio - March 15th, 2024
- CuSTOM Organoid Research Evolving From Tool to Treatment - Research Horizons - Research Horizons - March 15th, 2024
- BioCardia and StemCardia Announce Partnership to Deliver Cell-Gene Therapy for Remuscularization of Heart - Cath Lab Digest - March 15th, 2024
- Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine ... - Business Wire - March 13th, 2024
- Iron restriction keeps blood stem cells young, researchers find - Phys.org - March 13th, 2024
- Vitamin A could have a key role in both stem cell biology and wound healing: Study - Medical Dialogues - March 9th, 2024
- Trends in Stem Cell Transplantation Refusal for Myeloma Treatment - Targeted Oncology - March 7th, 2024
- Stem Cell Therapy Market (CAGR) of 31.1%, Future of Market Size Emerging Technologies and their Impact on ... - Taiwan News - March 7th, 2024
- This Swedish startup wants to reduce the cost, and controversy, around stem cell production - TechCrunch - March 6th, 2024
- Advancing stem cell therapy: The regulatory process to get to clinical trials - The Economic Times - March 6th, 2024
- Transitioning from traditional surgical methods to the innovative use of stem cells - pharmaphorum - March 6th, 2024
- 'Mini organs' are grown from human stem cells taken during the late stages of pregnancy for the first time - m - Daily Mail - March 6th, 2024
- Stem cell transplant cures man of HIV and leukemia, one of five to achieve full remission - Fox 28 - March 3rd, 2024
- Stem Cell Therapy Market to Boost USD 137.5 Billion by 2034 and Projected to grow at 32.10% CAGR with increasing ... - Yahoo Finance - March 1st, 2024
- Studies expand use of stem cell therapies - WPLG Local 10 - March 1st, 2024
- Innovative therapy targets and destroys leukemia stem cells - News-Medical.Net - February 27th, 2024
- Unlocking the Potential of Stem Cells: The Medical Revolution of the Century - EIN News - February 27th, 2024
- Pelage Pharmaceuticals Announces $16.75M Series A Financing led by GV to Revolutionize Regenerative Medicine ... - Yahoo Finance - February 27th, 2024
- Say Her Name - Henrietta Lacks, The Real Mother Of Stem - Her Campus - February 27th, 2024
- California Man Free of HIV And Cancer in Astonishing Medical Recovery - ScienceAlert - February 25th, 2024
- $93 million for research into improved health for children, young people and the aged, medical devices, mental health ... - Department of Health - February 25th, 2024
- Stem Cells in Regenerative Medicine - PMC - National Center for ... - February 24th, 2024
- The Promise and Reality of Stem Cell Therapy: What You Need to Know - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy: A Beacon of Hope for Patients with Untreatable Conditions - Corporate Wellness Magazine - February 22nd, 2024
- Leading Experts in Stem Cell Therapy: A Global Overview - Corporate Wellness Magazine - February 22nd, 2024
- Can Stem Cells Help Reverse the Effects of Aging? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy for Cancer: Hope on the Horizon? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cells and Autism: A Closer Look at Innovative Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Regrowth and Restoration: The Science Behind Stem Cell Therapy for Hair - Corporate Wellness Magazine - February 22nd, 2024
- Brain Recovery: The Role of Stem Cells in Stroke and Cerebral Palsy Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Turning Back the Clock: The Science of Stem Cells in Anti-Aging - Corporate Wellness Magazine - February 22nd, 2024
- Insights into cellular therapies for cancer treatment - Drug Target Review - February 22nd, 2024
- The Role of Stem Cells in Rheumatoid Arthritis Recovery - Corporate Wellness Magazine - February 22nd, 2024
- Dr Ernesto Romeros vision transforms immunotherapy regenerative medicine into a global leader in stem cell treatment - Khaleej Times - February 22nd, 2024
- World-Renowned Doctors Leading the Way in Stem Cell Research and Treatment - Medical Tourism Magazine - February 20th, 2024
- Choosing the Best: A Guide to America's Premier Stem Cell Therapy Providers - Medical Tourism Magazine - February 20th, 2024
- Navigating Through the Possibilities of Stem Cell Treatment for Eye Disorders - Medical Tourism Magazine - February 20th, 2024
- Global Leaders in Stem Cell Therapy: Where Excellence Meets Innovation - Medical Tourism Magazine - February 20th, 2024
- Excellence in Stem Cell Treatment: How the US is Pioneering Global Healthcare Solutions - Medical Tourism Magazine - February 20th, 2024
- Clarifying Memory Loss Treatments: The Role of Stem Cells - Medical Tourism Magazine - February 20th, 2024
- Battling Inflammation: Stem Cell Therapy for Rheumatoid Arthritis - Medical Tourism Magazine - February 20th, 2024
- Digestive Health and Stem Cells: Treating Ulcerative Colitis and Crohn's Disease - Medical Tourism Magazine - February 20th, 2024
- Top Stem Cell Clinics in the USA: Pioneering Treatments for Chronic Conditions - Medical Tourism Magazine - February 20th, 2024
- Stem Cells and Autism: Understanding the Potential for Innovative Treatments - Medical Tourism Magazine - February 20th, 2024
- Stopping the awakening of sleeping Acute Myeloid Leukaemia stem cells to prevent disease relapse - University of Birmingham - February 20th, 2024
- City of Hope Achieves Ground Breaking Treatment for Blood Cancer and HIV - Medriva - February 18th, 2024
- Regenerative Medicine Market Size to Worth USD 95 Billion by 2032 - InvestorsObserver - February 18th, 2024
- North America Organoids Market Projected to Reach US$ 5.35 Billion by 2030, Riding on a CAGR of 21.5% - GlobeNewswire - February 18th, 2024
- Chinese team tests lung treatment that may be first to reverse COPD damage - South China Morning Post - February 15th, 2024
- Why leukemic stem cells not harmed by chemotherapy begin to grow and produce AML cells after treatment - Medical Xpress - February 15th, 2024
- Regenerative Medicine Market is Expected to Reach $49.0 Billion | MarketsandMarkets - Yahoo Finance - February 15th, 2024
- Study finds interleukin-24 enhances CAR-T cell therapy's effectiveness against cancer stem cells - News-Medical.Net - February 15th, 2024
- Oldest Patient 'Cured' of HIV Still in Remission 5 Years After Transplant for AML - Medpage Today - February 15th, 2024
- Drug used for cocaine addiction may pave way for new treatment of advanced colon cancer - EurekAlert - February 15th, 2024
- Hematopoietic Stem Cells and Their Role in Development and Disease Therapy - The Scientist - February 15th, 2024
- Biomedical Researcher Seeks to Improve Outcomes in Stem Cell Treatments - University of Arkansas Newswire - February 13th, 2024
- Top 3 grants in regenerative medicine: January 2024 - RegMedNet - February 13th, 2024
- Scalise returning to Washington next week with cancer in complete remission - The Hill - February 13th, 2024
- Unlocking the power of stem cell therapy - Drug Target Review - February 9th, 2024
Recent Comments